CVD EQUIPMENT CORP - Quarter Report: 2019 September (Form 10-Q)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One) |
|
☑ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
For the quarterly period ended September 30, 2019
|
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
For the transition period from ____ to _____ |
Commission file number: 1-16525
CVD EQUIPMENT CORPORATION
(Name of Registrant in Its Charter)
New York |
11-2621692 |
State or Other Jurisdiction of |
(I.R.S. Employer Identification No.) |
355 South Technology Drive Central Islip, New York 11722
|
|
(Address of principal executive offices) |
(631) 981-7081
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock |
CVV |
NASDAQ Capital Market |
Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No☐
Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act).
Large accelerated filer ☐ |
Accelerated filer ☐ |
|
Non-accelerated filer ☑ |
Smaller reporting company ☑ |
Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☑
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 6,564,566 shares of Common Stock, $0.01 par value at November 8, 2019.
CVD EQUIPMENT CORPORATION AND SUBSIDIARIES
Index
Part I - Financial Information |
|
Item 1 – Financial Statements (Unaudited) |
|
|
|
Condensed Consolidated Balance Sheets at September 30, 2019 and December 31, 2018 |
3 |
|
|
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2019 and 2018 |
4 |
Condensed Consolidated Statement of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2019 and 2018 | 5 |
|
|
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2019 and 2018 |
6 |
|
|
Notes to Condensed Consolidated Financial Statements |
7 |
|
|
Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations |
18 |
Item 3 – Quantitative and Qualitative Disclosures About Market Risk |
26 |
Item 4 – Controls and Procedures |
26 |
|
|
Part II - Other Information |
28 |
|
|
Item 1 – Legal Proceedings |
28 |
Item 1A-Risk Factors |
28 |
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds |
28 |
Item 3 – Defaults Upon Senior Securities |
28 |
Item 4 – Mine Safety Disclosures |
28 |
Item 5 – Other Information |
28 |
Item 6 – Exhibits |
28 |
|
|
Signatures |
30 |
|
|
Exhibit Index |
31 |
PART 1 – FINANCIAL INFORMATION
Item 1 – Financial Statements
CVD EQUIPMENT CORPORATION AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited) | ||||||||
September 30, 2019 |
December 31, 2018 |
|||||||
ASSETS |
||||||||
Current Assets |
||||||||
Cash and cash equivalents |
$ | 6,739,065 | $ | 11,439,361 | ||||
Accounts receivable, net |
3,072,178 | 4,065,220 | ||||||
Contract assets |
2,587,783 | 1,357,797 | ||||||
Inventories |
1,769,215 | 1,861,873 | ||||||
Other current assets |
311,514 | 723,204 | ||||||
Total Current Assets |
14,479,755 | 19,447,455 | ||||||
Property, plant and equipment, net |
31,786,067 | 30,402,558 | ||||||
Deferred income taxes |
2,803,414 | 2,104,414 | ||||||
Other assets |
34,948 | 64,583 | ||||||
Intangible assets, net |
429,570 | 495,552 | ||||||
Total Assets |
$ | 49,533,754 | $ | 52,514,562 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
Current Liabilities |
||||||||
Accounts payable |
$ | 1,031,075 | $ | 713,194 | ||||
Accrued expenses |
1,706,514 | 1,503,309 | ||||||
Current maturities of long-term debt |
670,026 | 857,590 | ||||||
Contract liabilities |
143,333 | 536,524 | ||||||
Deferred revenue |
1,274,025 | 459,899 | ||||||
Total Current Liabilities |
4,824,973 | 4,070,516 | ||||||
Long-term debt, net of current portion |
11,547,683 | 12,051,720 | ||||||
Total Long-Term Liabilities |
11,547,683 | 12,051,720 | ||||||
Total Liabilities |
16,372,656 | 16,122,236 | ||||||
Commitments and contingencies |
||||||||
Stockholders’ Equity: |
||||||||
Common stock - $0.01 par value – 20,000,000 shares authorized; issued and outstanding 6,564,566 at September 30, 2019 and 6,535,888 at December 31, 2018 |
65,645 | 65,358 | ||||||
Additional paid-in capital |
26,624,426 | 26,148,256 | ||||||
Retained earnings |
6,471,027 | 10,178,712 | ||||||
Total Stockholders’ Equity |
33,161,098 | 36,392,326 | ||||||
Total Liabilities and Stockholders’ Equity |
$ | 49,533,754 | $ | 52,514,562 |
The accompanying notes are an integral part of these condensed consolidated financial statements
CVD EQUIPMENT CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended |
Nine Months Ended |
|||||||||||||||
September 30, |
September 30, |
|||||||||||||||
2019 |
2018 |
2019 |
2018 |
|||||||||||||
Revenue |
$ | 5,704,882 | $ | 4,027,768 | $ | 14,100,261 | $ | 19,616,879 | ||||||||
Cost of revenue |
4,305,059 | 4,083,752 | 12,595,340 | 14,795,731 | ||||||||||||
Gross profit |
1,399,823 | (55,984 | ) | 1,504,921 | 4,821,148 | |||||||||||
Operating expenses |
||||||||||||||||
Research and development |
112,724 | 240,613 | 453,724 | 465,536 | ||||||||||||
Selling and shipping |
175,760 | 331,280 | 680,183 | 1,244,004 | ||||||||||||
General and administrative |
1,359,910 | 2,225,593 | 4,728,021 | 6,434,123 | ||||||||||||
Total operating expenses |
1,648,394 | 2,797,486 | 5,861,928 | 8,143,663 | ||||||||||||
Operating loss |
(248,571 | ) | (2,853,470 | ) | (4,357,007 | ) | (3,322,515 | ) | ||||||||
Other income (expense): |
||||||||||||||||
Interest income |
26,774 | 40,720 | 115,643 | 86,994 | ||||||||||||
Interest expense |
(124,449 | ) | (114,692 | ) | (365,255 | ) | (355,325 | ) | ||||||||
Other income |
207,237 | - | 207,237 | - | ||||||||||||
Total other income (expense), net |
109,562 | (73,972 | ) | (42,375 | ) | (268,331 | ) | |||||||||
Loss before income tax |
(139,009 | ) | (2,927,442 | ) | (4,399,382 | ) | (3,590,846 | ) | ||||||||
Income tax benefit |
(1,000 | ) | (424,640 | ) | (691,697 | ) | (315,922 | ) | ||||||||
Net loss |
$ | (138,009 | ) | $ | (2,502,802 | ) | (3,707,685 | ) | $ | (3,274,924 | ) | |||||
Basic loss per common share |
$ | (0.02 | ) | $ | (0.39 | ) | $ | (0.57 | ) | $ | (0.51 | ) | ||||
Diluted loss per common share |
$ | (0.02 | ) | $ | (0.39 | ) | $ | (0.57 | ) | $ | (0.51 | ) | ||||
Weighted average common shares |
||||||||||||||||
Outstanding-basic |
6,556,767 | 6,494,986 | 6,550,279 | 6,482,870 | ||||||||||||
Weighted average common shares |
||||||||||||||||
Outstanding-diluted |
6,556,767 | 6,494,986 | 6,550,279 | 6,482,870 |
The accompanying notes are an integral part of these condensed consolidated financial statements
CVD EQUIPMENT CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited)
Three months ended September 30, 2019 and 2018 |
||||||||||||||||||||
Common stock |
||||||||||||||||||||
Shares |
Par Value |
Additional paid-in Capital |
Retained Earnings |
Total |
||||||||||||||||
Balance at July 1, 2019 |
6,555,150 | $ | 65,551 | $ | 26,525,521 | $ | 6,609,036 | $ | 33,200,108 | |||||||||||
Net loss |
- | - | - | (138,009 | ) | (138,009 | ) | |||||||||||||
Share-Based Compensation |
9,416 | 94 | 98,905 | - | 98,999 | |||||||||||||||
Balance at September 30, 2019 |
6,564,566 | $ | 65,645 | $ | 26,624,426 | $ | 6,471,027 | $ | 33,161,098 | |||||||||||
Balance at July 1, 2018 |
6,486,189 | $ | 64,862 | $ | 25,633,056 | $ | 14,607,611 | $ | 40,305,529 | |||||||||||
Net loss |
- | - | - | (2,502,802 | ) | (2,502,802 | ) | |||||||||||||
Share-Based Compensation |
10,143 | 101 | 279,451 | - | 279,552 | |||||||||||||||
Balance at September 30, 2018 |
6,496,332 | $ | 64,963 | $ | 25,912,507 | $ | 12,104,809 | $ | 38,082,279 |
Nine months ended September 30, 2019 and 2018 |
||||||||||||||||||||
Common stock |
||||||||||||||||||||
Shares |
Par Value |
Additional paid-in Capital |
Retained Earnings |
Total |
||||||||||||||||
Balance at January 1, 2019 |
6,535,888 | $ | 65,358 | $ | 26,148,256 | $ | 10,178,712 | $ | 36,392,326 | |||||||||||
Net loss |
- | - | - | (3,707,685 | ) | (3,707,685 | ) | |||||||||||||
Share-Based Compensation |
28,678 | 287 | 476,170 | - | 476,457 | |||||||||||||||
Balance at September 30, 2019 |
6,564,566 | $ | 65,645 | $ | 26,624,426 | $ | 6,471,027 | $ | 33,161,098 | |||||||||||
Balance at January 1, 2018 |
6,458,714 | $ | 64,587 | $ | 25,209,316 | 15,379,733 | 40,653,636 | |||||||||||||
Net loss |
- | - | - | (3,274,924 | ) | (3,274,924 | ) | |||||||||||||
Share-Based Compensation |
37,618 | 376 | 703,191 | - | 703,567 | |||||||||||||||
Balance at September 30, 2018 |
6,496,332 | $ | 64,963 | $ | 25,912,507 | $ | 12,104,809 | $ | 38,082,279 |
The accompanying notes are an integral part of these condensed consolidated financial statements
CVD EQUIPMENT CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine Months Ended |
||||||||
September 30, |
||||||||
2019 |
2018 |
|||||||
Cash flows from operating activities: |
||||||||
Net loss |
$ | (3,707,685 | ) | $ | (3,274,924 | ) | ||
Adjustments to reconcile net loss to net cash |
||||||||
(used in) provided by operating activities |
||||||||
Stock-based compensation |
476,458 | 703,567 | ||||||
Depreciation and amortization |
798,206 | 824,861 | ||||||
Deferred income tax |
(699,000 | ) | (315,922 | ) | ||||
Recovery of contingent earnout |
(200,000 | ) | - | |||||
(Increase)/decrease in operating assets |
||||||||
Accounts receivable |
993,042 | (528,751 | ) | |||||
Contract assets |
(1,229,987 | ) | 5,845,869 | |||||
Inventories |
92,658 | 214,119 | ||||||
Other current assets |
411,690 | (225,542 | ) | |||||
Other assets |
29,635 | (6,800 | ) | |||||
Increase/(decrease) in operating liabilities |
||||||||
Accounts payable |
317,881 | 86,417 | ||||||
Accrued expenses |
203,205 | (960,710 | ) | |||||
Contract liabilities |
(393,191 | ) | (237,098 | ) | ||||
Deferred revenue |
814,126 | 598,494 | ||||||
Total adjustments |
1,614,723 | 5,998,504 | ||||||
Net cash (used in) provided by operating activities |
(2,092,962 | ) | 2,723,580 | |||||
Cash flows from investing activities: |
||||||||
Purchases of property, plant and equipment |
(2,115,733 | ) | (2,258,379 | ) | ||||
Net cash used in investing activities |
(2,115,733 | ) | (2,258,379 | ) | ||||
Cash flows from financing activities: |
||||||||
Payments of long-term debt |
(491,601 | ) | (483,930 | ) | ||||
Net cash used in financing activities |
(491,601 | ) | (483,930 | ) | ||||
Net (decrease) in cash and cash equivalents |
(4,700,296 | ) | (18,729 | ) | ||||
Cash and cash equivalents at beginning of period |
11,439,361 | 14,210,909 | ||||||
Cash and cash equivalents at end of period |
$ | 6,739,065 | $ | 14,192,180 | ||||
Supplemental disclosure of cash flow information: |
||||||||
Income taxes paid |
$ | - | $ | 395,000 | ||||
Interest paid |
$ | 365,255 | $ | 355,322 | ||||
Supplemental disclosure of non-cash investing and financing activities: |
||||||||
Capitalization of right to use Asset |
$ | 103,937 | $ | - |
The accompanying notes are an integral part of these condensed consolidated financial statements
CVD EQUIPMENT CORPORATION AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
NOTE 1: |
BASIS OF PRESENTATION |
The accompanying unaudited condensed consolidated financial statements for CVD Equipment Corporation and Subsidiaries (collectively “the Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. They do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary in order to make the interim financials not misleading have been included and all such adjustments are of a normal recurring nature. The operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that can be expected for the year ending December 31, 2019.
The consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements at such date, but does not contain all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. For further information, please refer to the consolidated financial statements and notes thereto included in the Company’ Annual Report on Form 10-K for the year ended December 31, 2018, including the accounting policies followed by the Company as set forth in Note 2 to the consolidated financial statements contained therein.
All material intercompany balances and transactions have been eliminated in consolidation. In addition, certain reclassifications have been made to prior period consolidated financial statements to conform to the current period presentation.
NOTE 2: |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
Revenue Recognition
The Company designs, manufactures and sells custom chemical vapor deposition equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within three to eighteen months from commencement of order acceptance. The Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. Under this method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations.
NOTE 2: |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) |
Revenue Recognition (continued)
Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as indirect labor, supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work in process as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated.
“Contract assets,” include unbilled amounts typically resulting from system sales under contracts and revenue recognized exceeds the amount billed to the customer. The amount may not exceed their estimated net realizable value. Contract assets are classified as current based on our contract operating cycle.
“Contract liabilities,” include advance payments and billings in excess of revenue recognized. Contract liabilities are classified as current based on our contract operating cycle and reported on a contract-by-contract basis, net of revenue recognized, at the end of each reporting period.
For non-system sales of products or services, revenue is recognized when control of the promised products or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer.
Research and Development
Research and development costs are expensed as incurred. Due to the highly technical nature of our projects, we use our technical staff in a dual role, and based on their contribution to the customer or research and development projects, their costs are charged accordingly to either cost of goods sold or research and development.
NOTE 2: |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) |
Recent Accounting Standards
In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326), which require that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the increase or decreases of expected credit losses that have taken place during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The amendments in this update are effective for fiscal years beginning after December 15, 2019 and interim periods within those annual periods. Early adoption for fiscal years beginning after December 15, 2018 is permitted. We are currently evaluating the effect of this update on our consolidated financial statements.
Recently Adopted Accounting Standards
In February 2016 the FASB issued ASU No. 2016-02, "Leases (Topic 842)" (ASU 2016-02). The primary difference between previous GAAP and ASU 2016-02 is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The guidance requires a lessee to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. When measuring assets and liabilities arising from a lease, a lessee (and a lessor) should include payments to be made in optional periods only if the lessee is reasonably certain to exercise an option to extend the lease or not to exercise an option to terminate the lease. Similarly, optional payments to purchase the underlying asset should be included in the measurement of lease assets and lease liabilities only if the lessee is reasonably certain to exercise that purchase option. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018. Lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply.
NOTE 2: |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) |
An entity that elects to apply the practical expedients will, in effect, continue to account for leases that commence before the effective date in accordance with previous GAAP unless the lease is modified, except that lessees are required to recognize a right-of-use asset and a lease liability for all operating leases at each reporting date based on the present value of the remaining minimum rental payments that were tracked and disclosed under previous GAAP. In addition, FASB has amended Topic 842 prior to it becoming effective. The effective date and transition requirements for these amendments to Topic 842 are the same as ASU 2016-02. The Company has one lease at its Denmark facility which currently expires at December 31, 2020 and has recognized a lease liability and a right-of-use asset representing its right to use the underlying asset for the lease term in the amount of $104,000.
We believe there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.
NOTE 3: |
CONCENTRATION OF CREDIT RISK |
Cash and cash equivalents
The Company had cash and cash equivalents of $6.7 million and $11.4 million at September 30, 2019 and December 31, 2018, respectively. The Company invests excess cash in U.S. treasury bills, certificates of deposit or money market accounts, all with original maturities of less than three months. Cash equivalents were $5.8 million and $8.9 million at September 30, 2019 and December 31, 2018, respectively.
The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount at risk at September 30, 2019 and December 31, 2018 was $5,017,000 and $6,920,000, respectively.
Sales concentration
Revenue from a single customer in any one period can exceed 10% of our total revenues. During the three and nine months ended September 30, 2019, two customers exceeded 10%, and in total represented 42.8% and 28.1% of revenues. For the three and nine months ended September 30, 2018, one customer represented approximately 27.1% and 34.7% of our revenues.
NOTE 3: |
CONCENTRATION OF CREDIT RISK (continued) |
Accounts receivable
The Company sells products and services to various companies across several industries in the ordinary course of business. The Company performs ongoing credit evaluations to assess the probability of accounts receivable collection based on a number of factors, including past transaction experience, evaluation of their credit history and review of the invoicing terms of the contract to determine the financial strength of its customers. The Company also maintains allowances for anticipated losses. At September 30, 2019 two customers each exceeded 10% of the accounts receivable balance, representing 47.9% in total, and at December 31, 2018 two customers represented approximately 42% of the accounts receivable balance.
NOTE 4: |
REVENUE FROM CONTRACTS WITH CUSTOMERS |
The following table represents a disaggregation of revenue from contracts with customers for the three and nine months ended September 30, 2019 and 2018:
(in thousands)
Three Months Ended |
Nine Months Ended |
|||||||||||||||
Category |
Sept. 30, 2019 |
Sept. 30, 2018 |
Sept. 30, 2019 |
Sept. 30, 2018 |
||||||||||||
Aerospace |
$ | 1,138 | $ | 429 | $ | 2,353 | $ | 6,508 | ||||||||
Industrial |
1,483 | 755 | 4,870 | 5,963 | ||||||||||||
Research |
757 | 503 | 2,596 | 2,378 | ||||||||||||
Point in time |
2,327 | 2,341 | 4,281 | 4,768 | ||||||||||||
Net Revenue |
$ | 5,705 | $ | 4,028 | $ | 14,100 | $ | 19,617 |
Judgment is required to evaluate assumptions including the amount of net contract revenues and the total estimated costs to determine our progress towards contract completion and to calculate the corresponding amount of revenue to recognize.
Changes in estimates for sales of systems occur for a variety of reasons, including but not limited to (i) build accelerations or delays, (ii) product cost forecast changes, (iii) cost related change orders or add-ons, or (iv) changes in other information used to estimate costs. Changes in estimates may have a material effect on the Company’s consolidated statements of operations.
NOTE 4: |
REVENUE FROM CONTRACTS WITH CUSTOMERS (continued) |
The table below outlines the impact on revenue of net changes in estimated transaction prices and input costs for systems related sales contracts (both increases and decreases) for the three and nine months ended September 30, 2019 and 2018, as well as the number of projects that comprise such changes. Also included in the table is the net change in estimate as a percentage of the aggregate revenue for such projects.
Three Months Ended |
Three Months Ended |
|||||||
(In thousands) |
Sept. 30, 2019 |
Sept. 30, 2018 |
||||||
(Decrease) increase in revenue from net changes in transaction prices |
$ | (3 | ) | $ | 71 | |||
Increase (decrease) in revenue from net changes in input cost estimates |
$ | 334 | $ | (1,170 | ) | |||
Net increase (decrease) in revenue from net Changes in estimates |
$ | 331 | $ | (1,099 | ) | |||
Number of projects |
27 | 15 | ||||||
Net change in estimate as a percentage of aggregate revenue for associated projects |
3.8 | % | (2.4% | ) |
Nine Months Ended |
Nine Months Ended |
|||||||
(In thousands) |
Sept. 30, 2019 |
Sept. 30, 2018 |
||||||
Increase in revenue from net changes in transaction prices |
$ | 1 | $ | 146 | ||||
(Decrease) in revenue from net changes in input cost estimates |
$ | (224 | ) | $ | (1,740 | ) | ||
Net (decrease) in revenue from net Changes in estimates |
$ | (223 | ) | $ | (1,594 | ) | ||
Number of projects |
18 | 15 | ||||||
Net change in estimate as a percentage of aggregate revenue for associated projects |
(3.6% | ) | (3.4% | ) |
For the three and nine months ended September 30, 2019 and 2018, revenue (decreased) increased by $331,000 and ($223,000) in 2019, respectively, and ($1,099,000) and ($1,594,000) in 2018, respectively, from net changes in transaction prices, input cost estimates, product cost overruns and product cost forecast changes related to redesign of certain systems.
NOTE 4: |
REVENUE FROM CONTRACTS WITH CUSTOMERS (continued) |
Contract Assets and Liabilities
Contract assets consist of (i) retainage which represent the earned, but unbilled, portion for which payment is deferred by the customer until certain contractual milestones are met; and (ii) unbilled receivables which represent revenue that has been recognized in advance of billing the customer, which is common for long-term contracts. Contract liabilities consist of customer advances and billings in excess of revenue recognized.
During the nine months ended September 30, 2019 and 2018, the increase (decrease) in contract assets of approximately $1.2 million and ($5.8 million), respectively, was primarily caused by additional billed receivables during the 2018 period, for those projects that certain milestones had been reached.
NOTE 5: |
INVENTORIES |
Inventories consist of: |
Sept. 30, 2019 |
December 31, 2018 |
|||||||
Raw materials |
$ | 1,439,113 | $ | 1,656,488 | ||||
Work-in-process |
330,102 | 205,385 | ||||||
Inventories |
$ | 1,769,215 | $ | 1,861,873 |
NOTE 6: |
ACCOUNTS RECEIVABLE, NET |
Accounts receivable are presented net of an allowance for doubtful accounts of approximately $24,000 as of September 30, 2019 and December 31, 2018. The allowance is based on prior experience and management’s evaluation of the collectability of accounts receivable. Management believes the allowance is adequate. However, future estimates may change based on changes in future economic conditions.
NOTE 7: |
LONG-TERM DEBT |
The Company has a loan agreement with HSBC which is secured by a mortgage on our Central Islip, NY headquarters. The loan is payable in 120 consecutive equal monthly installments of $25,000 in principal plus interest and a final balloon payment upon maturity in March 2022. The balances as of September 30, 2019 and December 31, 2018 were approximately $2.4 million and $2.7 million respectively. Interest accrues on the loan, at our option, at the variable rate of LIBOR plus 1.75% or Prime less 0.5% (3.95% and 2.18% at September 30, 2019 and December 31, 2018, respectively).
NOTE 7: |
LONG-TERM DEBT (continued) |
On November 30, 2017, the Company purchased the premises located at 555 North Research Place, Central Islip, NY. The purchase price of the building was $13,850,000 exclusive of closing costs. The Company’s newly formed wholly-owned subsidiary, 555 N Research Corporation (the “Assignee”) and the Islip IDA, entered into a Fee and Leasehold Mortgage and Security Agreement (the ”Loan”) with HSBC in the amount of $10,387,500, which was used to finance a portion of the purchase price to acquire the premises located at 555 North Research Place, Central Islip, New York. The Loan was evidenced by the certain note, dated November 30, 2017 (the “Note”), by and between Assignee and the Bank, and secured by a certain Fee and Leasehold Mortgage and Security Agreement (the “Mortgage”), dated November 30, 2017, as well as a collateral Assignment of Leases and Rents.
The Note is payable in 60 consecutive equal monthly installments of $62,481 including interest and a final balloon payment upon maturity in December 2022. The balance outstanding as of September 30, 2019 and December 31, 2018 were approximately $9.8 million and $10.0 million respectively. The Note bears interest for each Interest Period (as defined in the Note), at the fixed rate of 3.9148%. As a condition of the Bank making the Loan, the Company was required to guaranty Assignee’s obligations under the Loan pursuant that certain Unlimited Guaranty, dated November 30, 2017 (the “Guaranty”). On May 31, 2019, the Company entered into two sublease agreements for a portion of the CVD Materials facility. During the three and nine months ended September 30, 2019, the Company recognized $207,000 of rental income which commenced in June 2019. Commencing July 2019, the monthly rental income increased from $36,000 to approximately $67,000 per month, which includes both of the sublease agreements (eastside and westside), or approximately $800,000 per annum. On October 30, 2019, the Tenant exercised its option to terminate the eastside Lease, which termination will be effective as of December 31, 2019 (the “Termination”). The Lease was for a one-year term ending on June 30, 2020, and provided for an initial base monthly rent of $31,667 per month ($380,000 per annum)(See Note 12).
At December 31, 2018, the Company was not in compliance with the one financial covenant (fixed charge coverage ratio) contained in the Mortgage. On March 26, 2019 the Company received a waiver from HSBC until April 1, 2020. On August 5, 2019, the Company entered into a Mortgage Modification Agreement which replaced the former covenant with a Minimum Liquid Assets covenant. The Company is in compliance with its financial covenant under the mortgage at September 30, 2019.
NOTE 8: |
STOCK-BASED COMPENSATION EXPENSE |
The Company recorded as part of selling and general administrative expense $99,000 and $476,000 during the three and nine months ended September 30, 2019, respectively, and during the three and nine months ended September 30, 2018, $280,000 and $704,000, respectively, for the cost of employee and director services received in exchange for equity instruments based on the grant-date fair value of those instruments.
NOTE 9: |
INCOME TAXES |
The provision (benefit) for income taxes includes the following:
Nine Months Ended September 30, |
||||||||
2019 |
2018 |
|||||||
Current: |
||||||||
Federal |
$ | --- | $ | --- | ||||
State |
7,303 | --- | ||||||
Total current provision |
$ | 7,303 | $ | --- | ||||
Deferred: |
||||||||
Federal |
$ | (699,000 | ) | $ | (315,922 | ) | ||
State |
--- | ---- | ||||||
Total deferred (benefit) provision |
(699,000 | ) | (315,922 | ) | ||||
Income tax expense (benefit) provision |
$ | (691,697 | ) | $ | (315,922 | ) |
The Company’s foreign subsidiary, Tantaline CVD ApS incurred a loss of approximately $149,000 for the nine months ended September 30, 2019 which would provide a $33,000 deferred tax asset, based on the standard corporate tax rate of 22% in Denmark. For the nine months ended September 30, 2018 the Company had a loss of $513,000 with a deferred tax asset of $113,000. However, sufficient uncertainty exists as to the realizability of these assets such that a full valuation allowance has been necessary.
We continue to evaluate for potential utilization of the Company’s deferred tax asset on a quarterly basis, reviewing our economic models, including projections and timing of orders, the commencement of operations of the new CVD Materials segment and cost containment measures.
NOTE 10: |
EARNINGS PER SHARE |
Basic earnings per share is computed by dividing net earnings available to common shareholders (the numerator) by the weighted average number of common shares outstanding (the denominator) for the period presented. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potentially dilutive common shares had been issued.
Stock options to purchase 447,930 shares of common stock were outstanding and 267,930 were exercisable during the three and nine months ended September 30, 2019. Stock options to purchase 387,930 shares were outstanding and 227,930 were exercisable during the three and nine months ended September 30, 2018. For the three and nine months ended September 30, 2019 and 2018, no shares were included in the diluted earnings per share calculation as their effect would have been anti-dilutive.
NOTE 10: |
EARNINGS PER SHARE (continued) |
The dilutive potential common shares on options is calculated in accordance with the treasury stock method, which assumes that proceeds from the exercise of all options are used to repurchase common stock at market value. The number of shares remaining after the proceeds are exhausted represents the potential dilutive effect of the securities.
NOTE 11: |
SEGMENT REPORTING |
The Company operates through three (3) segments: CVD Equipment Corporation (“CVD”), Stainless Design Concepts (“SDC”) and CVD Materials Corporation (“Materials”). The CVD segment is utilized for chemical vapor deposition equipment manufacturing. SDC is the Company’s ultra-high purity manufacturing division in Saugerties, New York for gas control systems. The Materials segment was established to provide quartzware and material coatings for aerospace, medical, electronic and other applications. The Company evaluates performance based on several factors, of which the primary financial measure is income or (loss) before taxes.
The Company’s corporate administration activities are reported in the Eliminations and Unallocated column. These activities primarily include intercompany profit, expenses related to certain corporate officers and support staff, expenses related to the Company’s Board of Directors, stock option expense for shares granted to corporate administration employees, certain consulting expenses, investor and shareholder relations activities, and all of the Company’s legal, auditing and professional fees, and interest expense.
Three Months Ended September 30,
(In thousands)
Eliminations* and |
||||||||||||||||||||
2019 |
CVD |
SDC |
Materials |
Unallocated |
Consolidated |
|||||||||||||||
Assets |
$ | 36,389 | $ | 6,689 | $ | 6,465 | $ | (9 | ) | $ | 49,534 | |||||||||
Revenue |
4,376 | 1,100 | 404 | (175 | ) | 5,705 | ||||||||||||||
Operating income/(loss) |
231 | 254 | (137 | ) | (597 | ) | (249 | ) | ||||||||||||
Pretax income/(loss) |
226 | 260 | (28 | ) | (597 | ) | (139 | ) | ||||||||||||
2018 |
||||||||||||||||||||
Assets |
$ | 31,702 | $ | 6,288 | $ | 17,429 | $ | (9 | ) | $ | 55,410 | |||||||||
Revenue |
2,542 | 1,047 | 526 | (87 | ) | 4,028 | ||||||||||||||
Operating income/(loss) |
(1,835 | ) | 125 | (343 | ) | (801 | ) | (2,854 | ) | |||||||||||
Pretax income/(loss) |
(1,850 | ) | 125 | (442 | ) | (760 | ) | (2,927 | ) |
NOTE 11: |
SEGMENT REPORTING (continued) |
Nine Months Ended September 30,
(In thousands)
Eliminations*and |
||||||||||||||||||||
2019 |
CVD |
SDC |
Materials |
Unallocated |
Consolidated |
|||||||||||||||
Revenue |
$ | 9,588 | $ | 3,778 | $ | 1,375 | $ | (641 | ) | $ | 14,100 | |||||||||
Operating income/(loss) |
(2,328 | ) | 936 | (464 | ) | (2,501 | ) | (4,357 | ) | |||||||||||
Pretax income/(loss) |
(2,297 | ) | 951 | (552 | ) | (2,501 | ) | (4,399 | ) | |||||||||||
2018 |
||||||||||||||||||||
Revenue |
$ | 14,883 | $ | 4,151 | $ | 1,256 | $ | (673 | ) | $ | 19,617 | |||||||||
Operating income/(loss) |
(212 | ) | 535 | (1,505 | ) | (2,140 | ) | (3,322 | ) | |||||||||||
Pretax income/(loss) |
(266 | ) | 535 | (1,806 | ) | (2,053 | ) | (3,590 | ) |
*All elimination entries represent intersegment revenues eliminated in consolidation for external financial reporting.
NOTE 12: |
SUBSEQUENT EVENT |
As discussed in Note 7, the Company’s wholly owned subsidiary 555 N Research Corporation, had entered into a sub-lease agreement with ELM Freight Handlers Inc. (“Tenant”), dated as of May 31, 2019 (the “Lease”), concerning the east side of its facility located at 555 North Research Place, Central Islip, NY (the “Facility”). The Lease was for a one-year term ending on June 30, 2020, and provided for an initial base monthly rent of $31,667 per month ($380,000 per annum).
On October 30, 2019, the Tenant exercised its option to terminate the Lease, which termination will be effective as of December 31, 2019 (the “Termination”).
The sub-lease agreement by and between 555 N Research Corporation and the Tenant concerning the west side of the Facility, dated as of May 31, 2019, the terms of which are discussed in Note 7, will remain in full force and effect and will not be affected by the Termination.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Except for historical information contained herein, this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended. These statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous important assumptions and other important factors that could cause actual results to differ materially from those in the forward-looking statements. Important assumptions and other factors that could cause actual results to differ materially from those in the forward-looking statements, include but are not limited to: competition in the Company’s existing and potential future product lines of business; the Company’s ability to obtain financing on acceptable terms if and when needed; uncertainty as to the Company’s future profitability, uncertainty as to the future profitability of acquired businesses or product lines, uncertainty as to any future expansion of the Company. Other factors and assumptions not identified above were also involved in the derivation of these forward-looking statements and the failure of such assumptions to be realized as well as other factors may also cause actual results to differ materially from those projected. The Company assumes no obligation to update these forward looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. Past results are no guaranty of future performance. You should not place undue reliance on any forward-looking statements, which speak only as of the dates they are made. When used in this Report, the words “believes,” “anticipates,” “expects,” “estimates,” “plans,” “intends,” “will” and similar expressions are intended to identify forward-looking statements.
Results of Operations
Three and Nine Months Ended September 30, 2019 vs. September 30, 2018
Three Months Ended |
Nine Months Ended |
|||||||||||||||
September 30, |
September 30, |
|||||||||||||||
2019 |
2018 |
2019 |
2018 |
|||||||||||||
Revenue |
$ | 5,704,882 | $ | 4,027,768 | $ | 14,100,261 | $ | 19,616,879 | ||||||||
Cost of revenue |
4,305,059 | 4,083,752 | 12,595,340 | 14,795,731 | ||||||||||||
Gross profit |
1,399,823 | (55,984 | ) | 1,504,921 | 4,821,148 | |||||||||||
Operating expenses |
||||||||||||||||
Research and development |
112,724 | 240,613 | 453,724 | 465,536 | ||||||||||||
Selling and shipping |
175,760 | 331,280 | 680,183 | 1,244,004 | ||||||||||||
General and administrative |
1,359,910 | 2,225,593 | 4,728,021 | 6,434,123 | ||||||||||||
Total operating expenses |
1,648,394 | 2,797,486 | 5,861,928 | 8,143,663 | ||||||||||||
Operating loss |
(248,571 | ) | (2,853,470 | ) | (4,357,007 | ) | (3,322,515 | ) | ||||||||
Other income (expense): |
||||||||||||||||
Interest income |
26,774 | 40,720 | 115,643 | 86,994 | ||||||||||||
Interest expense |
(124,449 | ) | (114,692 | ) | (365,255 | ) | (355,325 | ) | ||||||||
Other Income |
207,237 | - | 207,237 | - | ||||||||||||
Total other income (expense), net |
109,562 | (73,972 | ) | (42,375 | ) | (268,331 | ) | |||||||||
Loss before income tax |
(139,009 | ) | (2,927,442 | ) | (4,399,382 | ) | (3,590,846 | ) | ||||||||
Income tax benefit |
(1,000 | ) | (424,640 | ) | (691,697 | ) | (315,922 | ) | ||||||||
Net loss |
$ | (138,009 | ) | $ | (2,502,802 | ) | (3,707,685 | ) | $ | (3,274,924 | ) |
Three Months Ended September 30, 2019 vs. September 30, 2018
Revenue
Our revenue for the three months ended September 30, 2019 was $5.7 million compared to $4.0 million for the three months ended September 30, 2018, resulting in an increase of 41.6% which was primarily attributable to increased revenue of $1.7 million from our CVD Equipment segment related to spare parts and equipment sales.
The revenue contributed for the three months ended September 30, 2019, by the CVD Equipment segment, of $4.4 million, which totaled 76.7% of our overall revenue, was 72.0% or $1.8 million more than the segment’s $2.5 million contribution made in the prior year, which totaled 63.1% of our overall revenue. This revenue increase is the result of $1.4 million and $.4 million from spare parts and equipment sales, respectively.
Revenue for our SDC segment was $.9 million in three months ended September 30, 2019 as compared to $1.0 million in three months ended September 30, 2018, a decrease of $.1 million.
Revenues for our CVD Materials segment were $.4 million in the three months ended September 30, 2019 as compared to $.5 million for the three months ended September 30, 2018, a decrease of $.1 million.
Gross Profit
Gross profit for the three months ended September 30, 2019 amounted to $1.4 million, with a gross profit margin of 24.5%, compared to a gross profit of ($55,984) and a gross profit margin of (1.4%) for the three months ended September 30, 2018. In addition to the higher level of sales during the quarter increasing our gross profit, we achieved improvements in our operating efficiencies, lowered our costs and achieved improved mix of product revenues resulting in our gross profit margin percentage improvement.
Research and Development, Selling and General and Administrative Expenses
Research and Development
Due to the technical development required on our custom orders, our research and development team and their expenses are charged to costs of goods sold when they are working directly on a customer project. When they are not working on a customer project, they work in our Application Laboratory and their costs are charged to research and development. For the three months ended September 30, 2019, our research and development expenses totaled $113,000 compared to $241,000 for the three months ended September 30, 2018.
Selling
Selling expenses were $.2 million or 3.1 % of the revenue for the three months ended September 30, 2019 as compared to $.3 million or 8.2% for the three months ended September 30, 2018. The decrease was primarily the result of reduced employee related costs and lower trade show expenses.
General and Administrative
General and administrative expenses for the three months ended September 30, 2019 were $1.4 million or 23.8% of revenue compared to $2.2 million or 55.3% for the three months ended September 30, 2018, a decrease of $.8 million. The decrease in these expenses is primarily the result of reductions in employees and the related payroll and benefit costs, decreased stock compensation costs of $181,000 and decreased outside systems and finance consulting costs of $84,000. In addition, a $200,000 reduction of expenses was the result of the recovery of a contingent earnout not achieved by MesoScribe Technologies.
Operating Loss
As a result of the increased revenues, improved gross profit margins and reduced expenses, we recorded an operating loss of ($.3 million) for the three months ended September 30, 2019 as compared to an operating loss of ($2.9 million) for the three months ended September 30, 2018,
Other income (expenses)
Other income (expenses) were $110,000 and ($74,000) for the three months ended September 30, 2019 and 2018, respectively. This increase in income is primarily the result of subleasing a portion of its CVD Materials facility and receiving $207,000 in rental income during 2019.
Income Taxes
For the three months ended September 30, 2019, we recorded an income tax benefit of $1,000 as compared to $425,000 for the three months ended September 30, 2018. For the three months ended September 30, 2019 and 2018, our tax rate was primarily affected by permanent differences related to contingent consideration liability in the three months ended September 30, 2019 related to MesoScribe Technologies and the effect of the Company’s foreign operations resulting in an effective tax rate of 1.0% and 14.5%, respectively.
While we have substantially reduced our net loss in the three months ended September 30, 2019 to $138,000, we continue to evaluate for potential utilization of the Company’s deferred tax asset on a quarterly basis, reviewing our economic models, including projections and timing of orders, the commencement of operations of the new CVD Materials segment and cost containment measures.
Net loss
As a result of the foregoing factors, we reported a net loss of ($.1 million), or ($0.02) per basic and diluted share, for the three months ended September 30, 2019, as compared to net loss of ($2.5 million), or ($0.39) per basic and diluted share for the three months ended September 30, 2018.
Nine Months Ended September 30, 2019 vs. September 30, 2018
Revenue
Our revenue for the nine months ended September 30, 2019 was $14.1 million compared to $19.6 million for the nine months ended September 30, 2018, resulting in a decrease of $5.5 million or 28.1% which was primarily attributable to the completion of orders received from our largest customer in the prior year.
The revenue contributed for the nine months ended September 30, 2019, by the CVD Equipment segment, of $9.6 million, which totaled 68.0% of our overall revenue, was 35.6% or $5.3 million less than the segment’s $14.9 million contribution made in the prior year, which totaled 75.9% of our overall revenue.
Revenue for our SDC segment was $3.3 million for the nine months ended September 30, 2019 as compared to $3.5 million for the nine months ended September 30, 2018, a decrease of $.2 million or 6.2%. The SDC segment represented 23.1% and 17.7% of our total revenue during the nine months ended September 30, 2019 and 2018, respectively.
Revenues for our CVD Materials segment were $1.3 million in the nine months ended September 30, 2019 as compared to $1.3 million for 2018.
Gross Profit
Gross profit for the nine months ended September 30, 2019 amounted to $1.5 million, with a gross profit margin of 10.6%, compared to a gross profit of $4.8 million and a gross profit margin of 24.6% for the nine months ended September 30, 2018. The decreased gross profit and gross profit margin were the result of the reduction in sales from our largest customer in the prior year, while costs, principally payroll, which decreased, remained at higher levels to support our anticipated expansion of the CVD Materials segment and future growth.
Research and Development, Selling and General and Administrative Expenses
Research and Development
Due to the technical development required on our custom orders, our research and development team and their expenses are charged to costs of goods sold when they are working directly on a customer project. When they are not working on a customer project, they work in our Application Laboratory and their costs are charged to research and development. For the nine months ended September 30, 2019, our research and development expenses totaled $454,000 compared to $465,000 for the nine months ended September 30, 2018.
Selling
Selling expenses were $.7 million or 4.8% of the revenue for the nine months ended September 30, 2019 as compared to $1.2 million or 6.3% for the nine months ended September 30, 2018. The decrease was primarily the result of reduced employee related costs and trade show expenses as a result of the overall lower sales.
General and Administrative
General and administrative expenses for the nine months ended September 30, 2019 were $4.7 million or 33.5% of revenue compared to $6.4 million or 32.8% for the nine months ended September 30, 2018, a decrease of $1.7 million. The decrease in these expenses is primarily the result of reductions in employees and the related payroll and benefit costs, decreased stock compensation costs of $227,000 and decreased outside systems and finance consulting costs of $142,000. In addition, a $200,000 reduction of expenses was the result of the recovery of a contingent earnout not achieved by MesoScribe Technologies.
Operating Loss
As a result of the decreased revenues and gross margins, we recorded an operating loss of ($4.4 million) for the nine months ended September 30, 2019 as compared to an operating loss of ($3.3 million) for the nine months ended September 30, 2018, which was driven primarily by the reduced revenue from our largest customer in the prior year.
Other (expenses)/Income
Other expenses were $42,000 and $268,000 for the nine months ended September 30, 2019 and 2018, respectively. This reduction in net expenses is primarily the result of subleasing a portion of its CVD Materials facility and receiving $207,000 in rental income during 2019.
Income Taxes
For the nine months ended September 30, 2019, we recorded an income tax benefit of $692,000 as compared to $316,000 for the nine months ended September 30, 2018. For the nine months ended September 30, 2019 and 2018, our tax rate was primarily affected by permanent differences related to contingent consideration liability in the nine months ended September 30, 2019 related to MesoScribe Technologies and the effect of its foreign operations resulting in an effective tax rate of 15.7% and 8.8%, respectively.
While we have substantially reduced our net loss in the three months ended September 30, 2019 to $138,000, we continue to evaluate for potential utilization of the Company’s deferred tax asset on a quarterly basis, reviewing our economic models, including projections and timing of orders, the commencement of operations of the new CVD Materials segment and cost containment measures.
Net loss
As a result of the foregoing factors, we reported net loss of ($3.7 million), or ($0.57) per basic and diluted share, for the nine months ended September 30, 2019, as compared to net loss of ($3.3 million), or ($0.51) per basic and diluted share for the nine months ended September 30, 2018.
Liquidity and Capital Resources
As of September 30, 2019, we had aggregate working capital of $9.7 million compared to aggregate working capital of $15.4 million at December 31, 2018. Our cash and cash equivalents at September 30, 2019 and December 31, 2018 were $6.7 million and $11.4 million, respectively. The decrease in working capital of $5.7 million is primarily attributable to the overall reduction in sales and resulting operating loss for the period and debt service payments of approximately $.9 million related to our investment in the CVD Materials building purchased on November 30, 2017. We have continued to invest in activities primarily related to preparing CVD Materials at the new location which commenced small scale operations during the third quarter of 2019. Our total capital invested in the nine months ended September 30, 2019 was $2.1 million, primarily related to building improvements and machinery for the CVD Materials operations and we also incurred operating costs of approximately $232,000, exclusive of interest expense. During the year, we received rental income of approximately $207,000.
Accounts receivable, net of allowance for doubtful accounts, decreased by $1.0 million or 24.4% at September 30, 2019, to $3.1 million compared to $4.1 million at December 31, 2018. This decrease is principally due to the timing of shipments and customer payments.
Inventories as of September 30, 2019 decreased by $100,000 to approximately $1.8 million.
We have a loan agreement with HSBC USA, N.A. (the “HSBC”) which is secured by a mortgage on our Central Islip headquarters at 355 South Technology Drive. The loan is payable in 120 consecutive equal monthly installments of $25,000 in principal plus interest and a final balloon payment upon maturity in March 2022. The balances as of September 30, 2019 and December 31, 2018 were approximately $2.4 million and $2.7 million respectively. Interest accrues on the loan, at our option, at the variable rate of LIBOR plus 1.75% or Prime less 0.5%.
On November 30, 2017, we purchased the premises located at 555 North Research Place, Central Islip, NY which is intended to house the CVD Materials segment. The purchase price of the land and the building was $13,850,000 exclusive of closing costs.
As part of the acquisition, our newly formed wholly-owned subsidiary, 555 N Research Corporation (the” Assignee”) and the Islip IDA, entered into a Fee and Leasehold Mortgage and Security Agreement (the ”Loan”) with HSBC in the amount of $10,387,500, which was used to finance a portion of the purchase price to acquire the premises located at 555 North Research Place, Central Islip, New York (the ”Premises”). The Loan was evidenced by the certain note, dated November 30, 2017 (the ”Note”), by and between Assignee and the Bank, and secured by a certain Fee and Leasehold Mortgage and Security Agreement, dated November 30, 2017 (the “Mortgage”), as well as a collateral Assignment of Leases and Rents (“Assignment of Leases”).
The Note is payable in 60 consecutive equal monthly installments of $62,481, including interest. The balances as of September 30, 2019 and December 31, 2018 were approximately $9.8 million and $10.0 million respectively. The Note bears interest for each Interest Period (as defined in the Note), at the fixed rate of 3.9148%. The maturity date for the Note is December 1, 2022. As a condition of the Bank making the Loan, we were required to guaranty Assignee’s obligations under the Loan.
At December 31, 2018, we were not in compliance with the single financial covenant (fixed charge coverage ratio) contained in the Mortgage. On March 26, 2019 the Company received a waiver from HSBC until April 1, 2020. On August 5, 2019, the Company entered into a Mortgage Modification Agreement which replaced the former covenant with a Minimum Liquid Assets covenant. The Company is in compliance with its obligations under the mortgage at September 30, 2019.
At December 31, 2018 we had reduced our employee headcount by 15% to 197 as compared to December 31, 2017. At September 30, 2019 we have further reduced our headcount by 15% to 168 employees, and we are continuing to evaluate our staffing levels to support the new CVD Materials facility which commenced small scale operations during the third quarter of 2019, and the level of current and expected orders. During the third quarter of 2019, we increased our revenue sequentially by $786,000 or 16.0% as compared to the second quarter of 2019, and with improved margins and reductions in expenses we reduced our net loss by $1.3 million or 90.1% to a net loss of $138,000. In addition, during the third quarter of 2019 we received orders of $7.9 million for future delivery, which exceeded our 2019 Q1 and Q2 orders of $6.5 million and $3.3 million, respectively. While we continue to monitor and take action to reduce our expenses, we believe that our cash and cash equivalent positions and cash flow from operations will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months of the filing date of this Form 10-Q.
Off-Balance Sheet Arrangements.
We have no off-balance sheet arrangements at this time.
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
Not applicable.
Item 4. |
Controls and Procedures. |
Evaluation of Disclosure Controls and Procedures
We maintain a system of disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). As required by Rule 13a-15(b) under the Exchange Act, management of the Company, under the direction of our Chief Executive Officer and Chief Financial Officer, reviewed and performed an evaluation of the effectiveness of design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q (the “Report”).
Based on that review and evaluation, our Chief Executive Officer and Chief Financial Officer, along with others in our management, have determined that as of the end of the period covered by this Report on Form 10-Q the disclosure controls and procedures were effective to provide reasonable assurance that such information is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding disclosures.
Since the first quarter of 2019, to remediate prior deficiencies, we have implemented the following changes, and monitored the results of those changes in each successive quarter up to the quarter ended September 30, 2019: (1) established stricter formal procedures with respect to how and when our management will communicate to the auditors and Audit Committee on a more timely basis, (2) adopted sufficient written policies and procedures for accounting and financial reporting, (3) appointed and /or designated additional qualified personnel to ensure timely filing of the reports that we file or submit under the Exchange Act, (4) added additional, multiple review levels, and (5) receive from the staff of the foreign subsidiary financial information on a weekly, monthly and quarterly basis in order to monitor more closely. In addition, during the first quarter of 2019, we have reevaluated our internal controls regarding the estimation of costs on contracts in progress and have implemented changes as needed, and have also monitored those results up to the quarter ended September 30, 2019.
Changes in Internal Controls
There were no changes in our internal controls over financial reporting as defined in Rule 13a-15(f) or Rule 15d-15(f) under the Exchange Act that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the internal controls over financial reporting.
Limitations on the Effectiveness of Controls
We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control systems are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.
CVD EQUIPMENT CORPORATION
PART II
OTHER INFORMATION
Item 1. |
Legal Proceedings. |
None.
Item 1A. |
Risk Factors. |
Not applicable for Smaller Reporting Companies.
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds. |
None.
Item 3. |
Defaults Upon Senior Securities. |
None.
Item 4. |
Mine Safety Disclosures. |
Not applicable.
Item 5. |
Other Information. |
None.
Item 6. |
Exhibits |
10.1 |
|
10.2 |
10.3 |
31.1* |
Certification of Leonard A. Rosenbaum, Chief Executive Officer, dated November 12, 2019 |
31.2* |
Certification of Thomas McNeill, Chief Financial Officer, dated November 12, 2019 |
32.1* |
32.2* |
101.1** |
XBRL Instance. |
101.SCH** |
XBRL Taxonomy Extension Schema. |
101.CAL** |
XBRL Taxonomy Extension Calculation. |
101.DEF** |
XBRL Taxonomy Extension Definition. |
101.LAB** |
XBRL Taxonomy Extension Labels. |
101.PRE** |
XBRL Taxonomy Extension Presentation. |
________________
* Filed herewith.
** Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not to be filed or part of a registration statement of prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, this 12th day of November 2019.
CVD EQUIPMENT CORPORATION | |||
|
|
|
|
|
By: |
/s/ Leonard A. Rosenbaum |
|
|
|
Leonard A. Rosenbaum |
|
|
|
Chief Executive Officer |
|
|
|
(Principal Executive Officer) |
|
|
|
|
|
|
By: |
/s/ Thomas McNeill |
|
|
|
Thomas McNeill |
|
|
|
Chief Financial Officer |
|
|
|
(Principal Financial and |
|
|
|
Accounting Officer) |
|
EXHIBIT INDEX
10.1 |
Mortgage Modification Agreement, dated as of August 5, 2019, by and between 555 N Research Corporation and HSBC Bank USA, National Association (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on August 5, 2019) |
10.2 |
Reaffirmation of Unlimited Continuing Guaranty, dated as of August 5, 2019, by and between CVD Equipment Corporation and HSBC Bank USA, National Association (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on August 5, 2019) |
10.3 |
Note Modification Agreement, dated as of August 5, 2019, by and between FAE Holdings 411519R and HSBC Bank USA, National Association (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on August 5, 2019) |
31.1* |
Certification of Leonard A. Rosenbaum, Chief Executive Officer, dated November 12, 2019 |
31.2* |
Certification of Thomas McNeill, Chief Financial Officer, dated November 12, 2019 |
32.1* |
Certification of Leonard A. Rosenbaum, Chief Executive Officer, dated November 12, 2019, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
32.2* |
Certification of Thomas McNeill, Chief Financial Officer, dated November 12, 2019, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
101.1** |
XBRL Instance. |
101.SCH** |
XBRL Taxonomy Extension Schema. |
101.CAL** |
XBRL Taxonomy Extension Calculation. |
101.DEF** |
XBRL Taxonomy Extension Definition. |
101.LAB** |
XBRL Taxonomy Extension Labels. |
101.PRE** |
XBRL Taxonomy Extension Presentation. |
________________
* Filed herewith.
** Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not to be filed or part of a registration statement of prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.
31